Secure Asset Management LLC Increases Position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Secure Asset Management LLC boosted its holdings in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 9.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 39,920 shares of the company’s stock after buying an additional 3,406 shares during the quarter. Secure Asset Management LLC’s holdings in Mirum Pharmaceuticals were worth $1,651,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. State Street Corp increased its position in Mirum Pharmaceuticals by 19.9% during the third quarter. State Street Corp now owns 1,793,728 shares of the company’s stock worth $69,955,000 after buying an additional 297,511 shares during the period. Charles Schwab Investment Management Inc. increased its holdings in shares of Mirum Pharmaceuticals by 5.5% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 328,161 shares of the company’s stock valued at $12,798,000 after acquiring an additional 17,149 shares during the period. Geode Capital Management LLC raised its position in Mirum Pharmaceuticals by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 936,197 shares of the company’s stock valued at $36,519,000 after purchasing an additional 29,017 shares during the last quarter. GSA Capital Partners LLP grew its position in Mirum Pharmaceuticals by 791.7% during the 3rd quarter. GSA Capital Partners LLP now owns 57,985 shares of the company’s stock worth $2,261,000 after purchasing an additional 51,482 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. grew its holdings in shares of Mirum Pharmaceuticals by 25.5% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 145,599 shares of the company’s stock worth $6,021,000 after buying an additional 29,545 shares during the last quarter.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $48.65 on Friday. The stock’s 50 day moving average price is $43.65 and its 200 day moving average price is $41.40. The firm has a market cap of $2.34 billion, a P/E ratio of -24.08 and a beta of 0.98. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34. Mirum Pharmaceuticals, Inc. has a 1 year low of $23.14 and a 1 year high of $49.27.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. The business had revenue of $90.38 million for the quarter, compared to the consensus estimate of $81.99 million. Mirum Pharmaceuticals had a negative net margin of 31.69% and a negative return on equity of 41.22%. The company’s quarterly revenue was up 89.4% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.57) earnings per share. On average, sell-side analysts expect that Mirum Pharmaceuticals, Inc. will post -1.45 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Jolanda Howe sold 2,500 shares of the stock in a transaction on Thursday, November 14th. The stock was sold at an average price of $47.10, for a total value of $117,750.00. Following the completion of the sale, the senior vice president now directly owns 2,426 shares in the company, valued at approximately $114,264.60. This represents a 50.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Christopher Peetz sold 7,489 shares of Mirum Pharmaceuticals stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total transaction of $320,678.98. Following the sale, the chief executive officer now directly owns 119,359 shares in the company, valued at $5,110,952.38. This trade represents a 5.90 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 19,706 shares of company stock valued at $875,697 in the last quarter. 22.87% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several brokerages have weighed in on MIRM. HC Wainwright reiterated a “buy” rating and issued a $66.00 target price on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Leerink Partners lifted their target price on shares of Mirum Pharmaceuticals from $47.00 to $49.00 and gave the company an “outperform” rating in a report on Thursday, October 17th. Citigroup increased their price target on shares of Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, Robert W. Baird boosted their target price on Mirum Pharmaceuticals from $44.00 to $50.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. Ten investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $57.10.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.